Therapeutic Advances in the Management of Relapsing Forms of Multiple Sclerosis

Release Date: 3/12/2021 Expiration Date: 3/11/2022 Provider Statement This continuing education activity is provided by   Support Statement This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation. Target Audience The intended audience for this activity is neurologists, neurology nursing professionals, pharmacists, physician assistants, and other health care professionals involved in the management …

Immune Dysfunction in Multiple Sclerosis: Modern Considerations in Treatment and Management

Released: January 11, 2021 Expires: January 11, 2022 Program Description This activity provides an overview of the role of the innate and adaptive immune systems in the development and progression of multiple sclerosis (MS), while exploring the therapeutic implications of immune dysfunction. MS immunotherapies are reviewed, with a focus on their mechanisms of action and …

Initiating or Switching Therapy in Multiple Sclerosis: New Evidence and Expert Insights

*US and Canadian HCPs* Release Date: November 30, 2020 Expiration Date: November 30, 2021 Intended Audience: Physicians and their teams providing care for patients with MS (PAs, NPs, nurses, pharmacists) Accompanying this activity are resources to provide evidence-based guidance on necessary laboratory evaluations needed before initiating or switching DMTs, as well as a guide for …

Examining the Evidence for Early Initiation of Disease-Modifying Therapy

RELEASE DATE: December 21, 2020 VALID FOR CREDIT THROUGH: December 21, 2021 Provided by The Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses and Spire Learning. This activity is supported by an educational grant from Genentech, a member of the Roche Group. PRIMARY AUDIENCE: This multidisciplinary educational initiative is targeted to …

Exploring the Use of Diagnostic Tools to Improve Early Detection of MS

RELEASE DATE: December 21, 2020 VALID FOR CREDIT THROUGH: December 21, 2021 Provided by The Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses and Spire Learning. This activity is supported by an educational grant from Genentech, a member of the Roche Group. PRIMARY AUDIENCE: This multidisciplinary educational initiative is targeted to …

Clinical Insights on When and How to Switch DMT in Patients With a Suboptimal Treatment Response

RELEASE DATE: December 21, 2020 VALID FOR CREDIT THROUGH: December 21, 2021 Provided by The Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses and Spire Learning. This activity is supported by an educational grant from Genentech, a member of the Roche Group. PRIMARY AUDIENCE: This multidisciplinary educational initiative is targeted to …

What Is Disease Modifying Therapy? Evidence-Based Disease Modification in Multiple Sclerosis

RELEASE DATE: December 30, 2020 VALID FOR CREDIT THROUGH: December 30, 2021 Provided by The Consortium of Multiple Sclerosis Centers and Catamount Medical Education. This activity is supported by an independent education grant from Sanofi Genzyme. Credit Available Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™ Nurses — maximum of 1.0 contact hours of continuing nursing …

The New Era of Neuromyelitis Optica Spectrum Disorder: Advances in Diagnosis and Treatment

RELEASE DATE: October 21, 2020 VALID FOR CREDIT THROUGH: October 21, 2021 Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disorder of the central nervous system characterized by immune-mediated demyelination and axonal damage predominantly targeting the optic nerves and spinal cord. To provide the most up-to-date information on the diagnosis and treatment of NMOSD, the …

Cases in Multiple Sclerosis Treatment: Evidence-Based Approaches to Optimal Care

Released: November 13, 2020 Expires: November 13, 2021 Provided by The Consortium of Multiple Sclerosis Centers and Catamount Medical Education. This activity is supported by an independent education grant from Sanofi Genzyme. Credit Available Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™ Nurses — 1.0 Nursing Contact Hours Pharmacists — 1.0 Contact Hours (.1 CEUs) All other …

Cannabis and MS: Helping Patients Understand Risks and Benefits Session 1: Fundamentals of Cannabis

CANNABIS AND MS: HELPING PATIENTS UNDERSTAND RISKS AND BENEFITS SESSION 1: FUNDAMENTALS OF CANNABIS RELEASE DATE: October 20, 2020 VALID FOR CREDIT THROUGH: October 31, 2021 SERIES DESCRIPTION MS health professionals may be involved in the decision-making process about cannabis and provide care to those with MS who use cannabis. However, numerous surveys indicate that …